Beyond Backups: Redefining Logistics in Advanced Therapies & Biologics

How do you scale a supply chain when an entire manufacturing run is for one patient, and the starting material is inside them?

In this episode of Out of the Lab, we dive deep into the messy, complex, and high-stakes world of cell and gene therapy (CGT) logistics. Joining us again is Tatyana Matveeva, Director of cGMP Operations at Harvard Medical School and Massachusetts General Hospital, to break down the nuanced complexities and differences of supply chain risks in cell/gene therapies, and biologics.

Tatyana challenges the industry's habit of oversimplifying supply chain security down to just "having duplicates," and introduces a much-needed framework: Risk Intelligence.

From the extreme environmental volatility of live biologics to the profound operational shift required for autologous therapies, this conversation is a masterclass in modern biotech operations.

Key Takeaways from This Episode:

• Beyond "Plan B": Why true supply chain security requires rigorous, realistic stress-testing across an asset's entire life cycle, not just a list of backup suppliers.

• The Biologics Paradox: How the extreme sensitivity of advanced therapies to light, temperature, and mechanical stress shifts patient access from a clinical question to a logistical one.

• Process Uniformity vs. Mastery: A deep dive into the autologous space, where the patient is the starting material, making variability inevitable and "process mastery" non-negotiable.

• The Human Supply Chain: Balancing the logistical benefits of centralized academic medical centers with the compounding financial and emotional burdens placed on traveling patients and their families.

About the Guest: Tatyana Matveeva is the Director of cGMP Operations at Harvard Medical School and Massachusetts General Hospital, specializing in the operational infrastructure, regulatory compliance, and scalability of advanced therapies. If you enjoyed this episode with her, listen to the first episode she was featured on.

Subscribe to Out of the Lab for more raw, unfiltered insights into the operational realities of cell and gene therapy. Don't forget to leave a review if you enjoyed the episode!

Timestamps / Chapters:

• 00:00 – Introduction: The operational challenges of personalized medicine.

• 01:59 – Moving beyond "secure duplicates" in clinical trials.

• 07:20 – The volatility of biologics and its direct impact on patient access.

• 13:04 – Implementing a "risk-intelligent" approach to prevent asset extinction.

• 27:18 – Autologous vs. Allogeneic: Why uniform processes can still be flawed.

• 33:00 – Centralized care: The reality of patients as part of the supply chain.

• 40:10 – International regulations, GMP harmonization, and public health impact.